AU2016252860B2 - Compositions and methods for inhibiting kinases - Google Patents

Compositions and methods for inhibiting kinases Download PDF

Info

Publication number
AU2016252860B2
AU2016252860B2 AU2016252860A AU2016252860A AU2016252860B2 AU 2016252860 B2 AU2016252860 B2 AU 2016252860B2 AU 2016252860 A AU2016252860 A AU 2016252860A AU 2016252860 A AU2016252860 A AU 2016252860A AU 2016252860 B2 AU2016252860 B2 AU 2016252860B2
Authority
AU
Australia
Prior art keywords
agents
compound
virus
mammal
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016252860A
Other languages
English (en)
Other versions
AU2016252860A1 (en
Inventor
Terence A. Kelly
Milton H. Werner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inhibikase Therapeutics Inc
Original Assignee
Inhibikase Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibikase Therapeutics Inc filed Critical Inhibikase Therapeutics Inc
Publication of AU2016252860A1 publication Critical patent/AU2016252860A1/en
Application granted granted Critical
Publication of AU2016252860B2 publication Critical patent/AU2016252860B2/en
Priority to AU2020286339A priority Critical patent/AU2020286339B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2016252860A 2015-04-23 2016-04-22 Compositions and methods for inhibiting kinases Active AU2016252860B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020286339A AU2020286339B2 (en) 2015-04-23 2020-12-14 Compositions and methods for inhibiting kinases

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562151659P 2015-04-23 2015-04-23
US62/151,659 2015-04-23
US201562182955P 2015-06-22 2015-06-22
US62/182,955 2015-06-22
PCT/US2016/028914 WO2016172528A1 (en) 2015-04-23 2016-04-22 Compositions and methods for inhibiting kinases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020286339A Division AU2020286339B2 (en) 2015-04-23 2020-12-14 Compositions and methods for inhibiting kinases

Publications (2)

Publication Number Publication Date
AU2016252860A1 AU2016252860A1 (en) 2017-09-21
AU2016252860B2 true AU2016252860B2 (en) 2020-09-17

Family

ID=57144281

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016252860A Active AU2016252860B2 (en) 2015-04-23 2016-04-22 Compositions and methods for inhibiting kinases
AU2020286339A Active AU2020286339B2 (en) 2015-04-23 2020-12-14 Compositions and methods for inhibiting kinases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020286339A Active AU2020286339B2 (en) 2015-04-23 2020-12-14 Compositions and methods for inhibiting kinases

Country Status (6)

Country Link
US (8) US9828370B2 (enExample)
EP (1) EP3286179A4 (enExample)
JP (1) JP6795518B2 (enExample)
AU (2) AU2016252860B2 (enExample)
CA (1) CA2980478C (enExample)
WO (1) WO2016172528A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016252860B2 (en) 2015-04-23 2020-09-17 Inhibikase Therapeutics, Inc. Compositions and methods for inhibiting kinases
WO2018081251A1 (en) * 2016-10-25 2018-05-03 Inhibikase Therapeutics, Inc. Compositions and methods for inhibiting kinases
US10855891B2 (en) 2016-11-21 2020-12-01 Samsung Electro-Mechanics Co., Ltd. Apparatus for controlling position of camera module
TW202039862A (zh) * 2018-11-12 2020-11-01 美商藍印藥品公司 受體酪氨酸激酶(kit)基因突變
JP2022523562A (ja) * 2019-03-05 2022-04-25 ホンイー アンド アソシエイツ エルエルシー 神経変性疾患および癌の治療のための化合物
CN115645393A (zh) * 2020-02-26 2023-01-31 上海科技大学 二氢杨梅素在抗冠状病毒中的应用
EP4138847A4 (en) * 2020-04-24 2024-05-22 Memorial Sloan Kettering Cancer Center Targeted therapy for the treatment & prevention of life-threatening complications of infection
CN112552283A (zh) * 2020-12-07 2021-03-26 天津羲泽润科技有限公司 一种新型替尼类药物的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070350A2 (en) * 2006-10-27 2008-06-12 The Board Of Regents Of The University Of Texas System Methods and compositions related to wrapping of dehydrons
WO2008079460A2 (en) * 2006-09-05 2008-07-03 Emory University Tyrosine kinase inhibitors for prevention or treatment of infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1805748B (zh) * 2003-06-13 2010-05-26 诺瓦提斯公司 作为raf激酶抑制剂的2-氨基嘧啶衍生物
CN102406648A (zh) 2010-09-21 2012-04-11 中国科学院生物物理研究所 甲磺酸伊马替尼在制备抗帕金森病药物中的应用
KR20150008406A (ko) 2012-05-15 2015-01-22 노파르티스 아게 Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
WO2014055938A1 (en) 2012-10-04 2014-04-10 Inhibikase Therapeutics, Inc. Novel compounds, their preparation and their uses
AU2016252860B2 (en) 2015-04-23 2020-09-17 Inhibikase Therapeutics, Inc. Compositions and methods for inhibiting kinases
WO2018081251A1 (en) 2016-10-25 2018-05-03 Inhibikase Therapeutics, Inc. Compositions and methods for inhibiting kinases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079460A2 (en) * 2006-09-05 2008-07-03 Emory University Tyrosine kinase inhibitors for prevention or treatment of infection
WO2008070350A2 (en) * 2006-10-27 2008-06-12 The Board Of Regents Of The University Of Texas System Methods and compositions related to wrapping of dehydrons

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAPIER, R. J. et al., "Low Doses of Imatinib Induce Myelopoiesis and Enhance Host Anti- microbial Immunity", PLOS PATHOGENS, vol. 11, no. 3, (2015-03-30), pages 1 - 27. *

Also Published As

Publication number Publication date
US10316031B2 (en) 2019-06-11
US10344027B2 (en) 2019-07-09
AU2020286339A1 (en) 2021-01-21
US20250250266A1 (en) 2025-08-07
US20180057488A1 (en) 2018-03-01
EP3286179A4 (en) 2018-08-29
US20160311816A1 (en) 2016-10-27
US10906896B2 (en) 2021-02-02
EP3286179A1 (en) 2018-02-28
AU2020286339B2 (en) 2021-10-21
AU2016252860A1 (en) 2017-09-21
US20230159514A1 (en) 2023-05-25
US11407747B2 (en) 2022-08-09
US9828370B2 (en) 2017-11-28
US20200031819A1 (en) 2020-01-30
US20210130343A1 (en) 2021-05-06
US20190055234A1 (en) 2019-02-21
WO2016172528A1 (en) 2016-10-27
CA2980478C (en) 2024-01-23
JP6795518B2 (ja) 2020-12-02
JP2018513868A (ja) 2018-05-31
US20190119266A1 (en) 2019-04-25
US11725005B2 (en) 2023-08-15
US10118923B2 (en) 2018-11-06
CA2980478A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
AU2020286339B2 (en) Compositions and methods for inhibiting kinases
JP6754864B2 (ja) Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物
AU2010286569B2 (en) Compounds and compositions as protein kinase inhibitors
US8309550B2 (en) Kinase inhibitors and their use as pharmaceutical agents
JP7036939B2 (ja) 癌細胞の成長抑制効果を示す新規なピリミジン誘導体及びそれを含む薬剤学的組成物
BRPI0720635A2 (pt) Compostos orgânicos e seus usos
AU2013326850B2 (en) Novel compounds, their preparation and their uses
AU2007233928A1 (en) 3-substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as kinase inhibitors
JP2019514951A (ja) 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体
US20210040102A1 (en) Imidazo-fused heterocycles and uses thereof
WO2025149082A1 (zh) 取代桥环类抑制剂及其制备方法和应用
JP2009532400A (ja) キナーゼ阻害剤としての３−非置換Ｎ−（アリール−もしくはヘテロアリール）−ピラゾロ［１，５−ａ］ピリミジン
AU2017350848B2 (en) Compositions and methods for inhibiting kinases
WO2010083645A1 (en) PYRIMIDO[5,4-e][1,2,4]TRIAZINES AND USES THEREOF
JP2022523562A (ja) 神経変性疾患および癌の治療のための化合物
HK40001081A (en) Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)